Clinical Trial Finds CBD Vaporization Doesn’t Negatively Impact Driving Performance and Vision
- The study was a randomized, double-blind, placebo-controlled crossover experiment that evaluated whether CBD impacts the ability to drive safely.
- 30 occasional CBD or cannabis users participated in the study, vaporizing a placebo, 15% CBD, or 30% CBD in three experimental sessions spaced a week apart.
- Driving performance was measured using an overall driving performance score (ODPS), with secondary outcomes including visual function metrics and other driving parameters.
- The study found that consuming vaporized cannabidiol in doses of 16 mg and 32 mg did not significantly affect simulated vehicle driving performance or visual function, with only a slight decrease in motion detection observed.
The randomized, double-blind, placebo-controlled crossover experiment assessed whether CBD impacts the ability to drive safely.
The study involved 30 participants with an average age of 26.2 years, 70% of whom were male. All participants were occasional CBD or cannabis users and held valid driving licenses. Over three experimental sessions spaced a week apart, participants vaporized a placebo, 15% CBD (16 mg), or 30% CBD (32 mg). Driving performance was evaluated using an overall driving performance score (ODPS), while secondary outcomes included various visual function metrics and other driving parameters. The findings showed no significant changes in ODPS after using either dose of CBD compared to the placebo. Visual function largely remained unaffected, except for a slight but statistically significant decrease in motion detection. Similarly, secondary driving outcomes, including lane control, reaction time, and collisions, showed no significant differences.
The study concludes by stating that “Consumption of vaporized cannabidiol in 16 mg and 32 mg doses does not appear to affect simulated vehicle driving performance and visual function.”